Literature DB >> 1270179

Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice.

I Gresser, C Maury, M Tovey.   

Abstract

Daily administration of potent mouse interferon preparations, begun after clinical diagnosis of lymphoma in AKR mice, increased average survival by approximately 100%. Interferon treatment delayed the evolution of the lymphoma but regression of tumour was not observed. The therapeutic effects observed with interferon in AKR mice compare favorably with reported results obtained using standard anti-cancer drugs.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1270179     DOI： 10.1002/ijc.2910170514

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Advances in interferon research - Medical Staff Conference.

Authors:  A A Creasey; T C Merigan
Journal:  West J Med       Date:  1982-03

2.  Enchancement of leukemogenesis in mice after prolonged administration of anti-interferon or normal rabbit globulin.

Authors:  A D Inglot; T Chudzio
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

3.  Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML).

Authors:  A Z Rohatiner; F R Balkwill; J S Malpas; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Single agent therapy of interferon for brain tumours: correlation between natural killer activity and clinical course.

Authors:  S Otsuka; H Handa; J Yamashita; K Suda; J Takeuchi
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

Review 5.  The management of follicular lymphoma.

Authors:  A Z Rohatiner; T A Lister
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Authors:  A Rohatiner; J Radford; D Deakin; H Earl; S B Love; O Price; A Wilson; T A Lister
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.